Mycobacterium tuberculosis Protein Ag85A-Pipeline Review, H2 2016

Mycobacterium tuberculosis Protein Ag85A-Pipeline Review, H2 2016


  • Products Id :- GMDHC0450TDB
  • |
  • Pages: 48
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Mycobacterium tuberculosis Protein Ag85A-Pipeline Review, H2 2016

Summary

Global Markets Direct's, Mycobacterium tuberculosis Protein Ag85A-Pipeline Review, H2 2016', provides in depth analysis on Mycobacterium tuberculosis Protein Ag85A targeted pipeline therapeutics.

The report provides comprehensive information on the Mycobacterium tuberculosis Protein Ag85A, targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Mycobacterium tuberculosis Protein Ag85A targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Mycobacterium tuberculosis Protein Ag85A

The report reviews Mycobacterium tuberculosis Protein Ag85A targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Mycobacterium tuberculosis Protein Ag85A targeted therapeutics and enlists all their major and minor projects

The report assesses Mycobacterium tuberculosis Protein Ag85A targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Mycobacterium tuberculosis Protein Ag85A targeted therapeutics

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Mycobacterium tuberculosis Protein Ag85A

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Mycobacterium tuberculosis Protein Ag85A development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Mycobacterium tuberculosis Protein Ag85A Overview 6

Therapeutics Development 7

Mycobacterium tuberculosis Protein Ag85A-Products under Development by Stage of Development 7

Mycobacterium tuberculosis Protein Ag85A-Products under Development by Therapy Area 8

Mycobacterium tuberculosis Protein Ag85A-Products under Development by Indication 9

Mycobacterium tuberculosis Protein Ag85A-Pipeline Products Glance 10

Early Stage Products 10

Mycobacterium tuberculosis Protein Ag85A-Products under Development by Companies 11

Mycobacterium tuberculosis Protein Ag85A-Products under Development by Universities/Institutes 13

Mycobacterium tuberculosis Protein Ag85A-Therapeutics Assessment 15

Assessment by Monotherapy/Combination Products 15

Assessment by Route of Administration 16

Assessment by Molecule Type 18

Mycobacterium tuberculosis Protein Ag85A-Companies Involved in Therapeutics Development 20

Imaxio SA 20

Mycobacterium tuberculosis Protein Ag85A-Drug Profiles 21

HG-85A-Drug Profile 21

Product Description 21

Mechanism Of Action 21

R&D Progress 21

HG-85A/B-Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

HG856-A-Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

HG856-BCG-Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

HG856-SeV-Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

IMX-313-TB-Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

MVA-85A-Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

TB/FLU-04L-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

tuberculosis vaccine-Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

tuberculosis vaccine-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

tuberculosis vaccine 2-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Mycobacterium tuberculosis Protein Ag85A-Dormant Projects 35

Mycobacterium tuberculosis Protein Ag85A-Discontinued Products 36

Mycobacterium tuberculosis Protein Ag85A-Featured News & Press Releases 37

Mar 24, 2015: World-first TB vaccination trials enter next stage 37

Oct 02, 2013: New tuberculosis vaccine will help fight 'serious public health threat' 38

Sep 03, 2013: Imaxio announces the first human clinical trial using its pro-immunogenic technology IMX313, in tuberculosis 39

Feb 04, 2013: Emergent BioSolutions Reports Publication Of Data From Phase IIb Clinical Trial For Tuberculosis Vaccine Candidate MVA85A In Lancet 39

Dec 10, 2012: University Of Cape Town Begins New study On TB Vaccine For Newborns Of HIV-positive Mothers 41

Mar 22, 2012: Emergent BioSolutions Receives NIAID Grant To Support Tuberculosis Vaccine Candidate 41

Aug 11, 2011: Aeras And Oxford-Emergent Tuberculosis Consortium Announce Start Of Phase IIb Trial Of New Investigational Tuberculosis Vaccine In Senegal And South Africa 42

Apr 28, 2011: Oxford-Emergent Tuberculosis Consortium Vaccinates Last Infant In Phase IIb Clinical Trial 43

Feb 25, 2011: Delegates From European Parliament Express Support For Rapid Development Of Emergent's New TB Vaccine 44

Apr 22, 2009: New TB Vaccine Candidate Enters Phase IIb Proof-of-Concept Trial in South Africa 44

Jun 23, 2008: Emergent BioSolutions And University of Oxford Form Joint Venture To Develop Advanced Tuberculosis Vaccine 45

Oct 25, 2004: TB Vaccine MVA85A Succeeds In Safety Trials 46

Appendix 47

Methodology 47

Coverage 47

Secondary Research 47

Primary Research 47

Expert Panel Validation 47

Contact Us 47

Disclaimer 48

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Products under Development by Companies, H2 2016 12

Number of Products under Investigation by Universities/Institutes, H2 2016 13

Products under Investigation by Universities/Institutes, H2 2016 14

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Stage and Route of Administration, H2 2016 17

Number of Products by Stage and Molecule Type, H2 2016 19

Pipeline by Imaxio SA, H2 2016 20

Dormant Projects, H2 2016 35

Discontinued Products, H2 2016 36

List of Figures

Number of Products under Development for, H2 2016 7

Comparative Analysis by Early Stage Products, H2 2016 10

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Routes of Administration, H2 2016 16

Number of Products by Stage and Routes of Administration, H2 2016 16

Number of Products by Molecule Types, H2 2016 18

Number of Products by Stage and Molecule Type, H2 2016 18

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Imaxio SA

Mycobacterium tuberculosis Protein Ag85A Therapeutic Products under Development, Key Players in Mycobacterium tuberculosis Protein Ag85A Therapeutics, Mycobacterium tuberculosis Protein Ag85A Pipeline Overview, Mycobacterium tuberculosis Protein Ag85A Pipeline, Mycobacterium tuberculosis Protein Ag85A Pipeline Assessment

select a license
Single User License
USD 3500 INR 251720
Site License
USD 7000 INR 503440
Corporate User License
USD 10500 INR 755160

NEWSLETTER BY CATEGORY




Testimonials

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com